AbbVie Inc. reports pharmaceutical developments across immunology, neuroscience, oncology and Allergan Aesthetics. Recurring updates include financial results by product portfolio, clinical and real-world data for therapies such as SKYRIZI and RINVOQ, FDA regulatory submissions and response letters, and medical-conference presentations in inflammatory bowel disease and other immune-mediated conditions.
Company news also covers pipeline spending, acquired in-process research and development, manufacturing capacity for medicines in core therapeutic areas, and investor conference appearances. AbbVie’s product references commonly include SKYRIZI, RINVOQ, Botox Therapeutic, Vraylar, Ubrelvy, Qulipta, Venclexta, Imbruvica and Elahere.
AbbVie (ABBV) announced results from two Phase 4 studies of aesthetic treatments in adults taking GLP-1 medications through Allergan Aesthetics. In HARMONY IN DIVERSITY's 30-person medical weight loss cohort, combined hyaluronic acid injectables, onabotulinumtoxinA and skincare improved average facial appearance satisfaction scores by 42.4 points, a statistically significant change measured 30 days after onabotulinumtoxinA treatment.
HALO's interim analysis of 25 of 75 treated participants showed a 39.6-point average improvement at month 3; 95.7% were satisfied or very satisfied they still looked like themselves. Both studies were open-label and single-arm, without a comparison group. Most treatment-related adverse events were mild and nonserious.
AbbVie (NYSE: ABBV) will present nine Allergan Aesthetics abstracts at the American Society for Dermatologic Surgery Annual Meeting on November 5–8 in San Diego.
Presentations include two Phase 4 studies examining aesthetic treatment in patients taking GLP-1-related medications for weight management, focusing on satisfaction and psychosocial outcomes. A digital image analysis will examine frown-line severity and brow position following investigational trenibotulinumtoxinE and BOTOX Cosmetic treatment. Other research covers combined aesthetic treatments, topical exosome skincare and abdominal body contouring. An expert panel will discuss changing consumer expectations and medical weight loss in aesthetics.
Brise Pharmaceuticals provided an update on its exclusive license agreement with AbbVie (NYSE: ABBV), covering two preclinical migraine programs.
The companies entered the agreement in 2024. Brise handles discovery, while AbbVie will lead global development and commercialization. The aggregate potential transaction value could reach up to US $757 million, including development, commercial, regulatory and sales milestones, plus royalties on future sales. Brise has already achieved several near-term milestones; the potential transaction value is not a disclosed payment received.
AbbVie (ABBV) reported third-quarter 2026 net revenues of $17.404 billion, up 10.3 percent on a reported basis from a year earlier. GAAP diluted earnings per share rose over 100.0 percent to $2.37; adjusted diluted EPS also rose over 100.0 percent to $3.82. Both included a $0.11 unfavorable impact from acquired in-process research and development and milestones expense.
Immunology revenues increased 16.3 percent and neuroscience revenues rose 19.4 percent, while aesthetics declined 1.4 percent, all on a reported basis. AbbVie completed its acquisition of Apogee Therapeutics and secured FDA approvals for Skyrizi subcutaneous induction in Crohn's disease and Juvmo in Parkinson's disease. AbbVie raised its 2026 adjusted EPS guidance to $13.95–$13.99 from $13.76–$13.96 and announced a 5.2 percent dividend increase beginning with the dividend payable in February 2027.
AbbVie (ABBV) announced that its Allergan Aesthetics business will hold BOTOX Cosmetic Day on November 18, 2026, with offers for Allē members.
Starting at 9 a.m. PT, members who buy a $50 gift card will receive another $50 gift card free, while supplies last. Cards are redeemable for future BOTOX Cosmetic treatments at participating Allē providers. A November referral offer gives members and their referred friends $50 off qualifying products or treatments. The friend must register and receive treatment November 1–30; each member is limited to one referral offer.
Allergan Aesthetics, an AbbVie (ABBV) company, named 20 women entrepreneurs as 2026 grant recipients of its BOTOX Cosmetic-funded Confidence Collective. Each recipient received $20,000 to support her business goals.
In the program's fourth year, 250 women entrepreneurs received coaching, business tools and guidance before a panel selected the grant recipients. Since 2023, the initiative has provided more than 500 women entrepreneurs with business-building resources and community connections and awarded more than $1.5 million in grants.
AbbVie (ABBV) submitted a U.S. FDA biologics license application for etentamig to treat adults with relapsed or refractory multiple myeloma.
The application is supported by the Phase 3 CERVINO study, which compared etentamig with investigator-selected standard therapies in patients exposed to three treatment classes after at least two prior treatment lines. Etentamig achieved statistically significant improvements in both primary measures: overall response was 74.0% versus 45.7%, and progression-free survival, the time without disease worsening, showed a 60% risk reduction. Treatment-emergent adverse events led to discontinuation in 3.6% versus 14%. Grade 3/4 infections occurred in 27.7% versus 19.2%, while grade 5 infections occurred in 1.5% versus 3.1%. Among patients receiving a single step-up dose, cytokine release syndrome occurred in 28.3%, with no grade 3 or higher events reported.
AbbVie (ABBV) is marking eight years of its Allergan Aesthetics business partnering with Girls Inc. on STEM education. A planned San Antonio workshop will bring together 20 participants and alumnae for career exploration and a private panel with local women healthcare providers.
SkinSpirit will support the partnership for a third consecutive year. From November 1–15, 2026, clients will be invited to donate directly to Girls Inc. to support science, technology, engineering and mathematics programming, mentorship and career exploration across the United States and Canada.
AbbVie (ABBV) received FDA approval for subcutaneous SKYRIZI induction treatment in adults with moderately to severely active Crohn's disease. Patients can now start treatment at home using an on-body injector. Induction dosing is 720 mg at weeks 0, 2, 4 and 8, followed by maintenance starting at week 12 and continuing every eight weeks.
In the Phase 3 AFFIRM trial, week-12 clinical remission was 56% with subcutaneous SKYRIZI versus 30% with placebo; endoscopic response, a measure of improvement seen during intestinal examination, was 43% versus 15%. Among patients without prior advanced therapy failure, these rates were 74% versus 27% and 60% versus 15%, respectively. No new safety risks were observed. The FDA also approved label changes across all approved indications allowing clinicians to determine whether pretreatment tuberculosis testing is needed using clinical judgment.
AbbVie (ABBV) reported that investigational lutikizumab met the primary endpoint in its Phase 3 INTREPID trial for moderate to severe hidradenitis suppurativa. At Week 16, 31.4% versus 23.4% on placebo achieved HiSCR75: at least a 75% reduction in abscesses and inflammatory nodules, without increased abscesses or draining fistulas (p≤0.001).
The trial enrolled 1,400 adults and adolescents and met 8 ranked secondary endpoints. At Week 8, 26.2% versus 15.0% achieved at least a 3-point skin-pain reduction. Flares occurred in 18.4% versus 28.1% over 16 weeks. Overall adverse-event rates were 53.4% versus 53.7%; serious-event rates were 3.0% versus 2.9%. No new safety concerns were identified. AbbVie expects extension data in 2027 to support regulatory submissions in the second half of that year.